Skip to content

Effects of bupivacaine liposome thoracic paravertebral nerve block on perioperative hemodynamics and postoperative analgesia in patients undergoing open-vision repair of atrial septal defect under extracorporeal circulation

Effects of bupivacaine liposome thoracic paravertebral nerve block on perioperative hemodynamics and postoperative analgesia in patients undergoing open-vision repair of atrial septal defect under extracorporeal circulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112278
Enrollment
Unknown
Registered
2025-11-12
Start date
2024-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial septal defect

Interventions

Bupivacaine Liposome Group:Ultrasound-guided unilateral thoracic paravertebral nerve block using bupivacaine liposomes
Ropivacaine hydrochloride group:Ultrasound-guided unilateral thoracic paravertebral nerve block using ropivacaine hydrochloride

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Elective thoracoscopic off-pump direct repair of atrial septal defect (ASD) or ASD repair combined with tricuspid valvuloplasty, ASD repair combined with correction of anomalous pulmonary venous drainage; 2. Age 18-55 years, any gender; 3. ASA classification II or III; 4. New York Heart Association (NYHA) functional class II or III; left ventricular ejection fraction (EF) >50%; 5. Postoperative ICU admission; 6. Planned hospital stay >24 hours after surgery.

Exclusion criteria

Exclusion criteria: 1. Refusal to participate; 2. Contraindications for paravertebral nerve block (thoracic infection; infectious disease of the skin or soft tissue at the puncture site, or tumor; unclear or abnormal anatomical location at the puncture site, or unclear surface markings; coagulation disorders; allergy to local anesthetics); 3. Long-term use of chronic pain medications; 4. History of cardiac surgery or previous cardiac surgery; 5. Emergency surgical patients; 6. History of chronic lung disease, with oxygen saturation <90% without supplemental oxygen; 7. Severe liver dysfunction (liver enzymes more than 3 times the upper limit of normal and serum albumin concentration below the reference range); 8. Severe renal insufficiency requiring preoperative renal replacement therapy; 9. Stroke, schizophrenia, depression, Parkinson's disease, epilepsy, or dementia; 10. Illiteracy, speech disorders, or severe hearing or vision impairment that prevents communication.

Design outcomes

Primary

MeasureTime frame
Postoperative myocardial markers and stress indicators ;MAP and HR at different time points in the perioperative period ;Perioperative opioid use ;Postoperative NRS scores ;

Secondary

MeasureTime frame
Duration of postoperative mechanical ventilation ;ICU stay time ;Hospital stay time ;Hospitalization expenses ;

Countries

China

Contacts

Public ContactYu Chen

The First Affiliated Hospital of Nanjing Medical University

chenyu020219@163.com+86 159 0280 9401

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026